Cargando…

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca’s ChAdOx1-nCov-19 (ChAd) only in in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barros-Martins, Joana, Hammerschmidt, Swantje I., Cossmann, Anne, Odak, Ivan, Stankov, Metodi V., Morillas Ramos, Gema, Dopfer-Jablonka, Alexandra, Heidemann, Annika, Ritter, Christiane, Friedrichsen, Michaela, Schultze-Florey, Christian, Ravens, Inga, Willenzon, Stefanie, Bubke, Anja, Ristenpart, Jasmin, Janssen, Anika, Ssebyatika, George, Bernhardt, Günter, Münch, Jan, Hoffmann, Markus, Pöhlmann, Stefan, Krey, Thomas, Bošnjak, Berislav, Förster, Reinhold, Behrens, Georg M. N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2021
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440184/ https://www.ncbi.nlm.nih.gov/pubmed/34262158 http://dx.doi.org/10.1038/s41591-021-01449-9

Ejemplares similares

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
por: Behrens, Georg M. N., et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination
por: Hammerschmidt, Swantje I., et al.
Publicado: (2021)

Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern
por: Odak, Ivan, et al.
Publicado: (2022)

Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals
por: Barros-Martins, Joana, et al.
Publicado: (2023)

Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents
por: Bošnjak, Berislav, et al.
Publicado: (2021)

Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals
por: Behrens, Georg M. N., et al.
Publicado: (2020)

Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage
por: Nehlmeier, Inga, et al.
Publicado: (2023)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

Robust induction of neutralizing antibodies against the SARS‐CoV‐2 Delta variant after homologous Spikevax or heterologous Vaxzevria‐Spikevax vaccination
por: Hammerschmidt, Swantje I., et al.
Publicado: (2022)

Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals
por: Behrens, Georg M. N., et al.
Publicado: (2020)

Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy
por: Jedicke, Nils, et al.
Publicado: (2021)

Hide and seek with SARS-CoV-2: spike receptor-binding domain-specific memory B cells still recognize Omicron variant
por: Odak, Ivan, et al.
Publicado: (2022)

Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
por: Strengert, Monika, et al.
Publicado: (2021)

Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods
por: Bošnjak, Berislav, et al.
Publicado: (2020)

Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination
por: Dulovic, Alex, et al.
Publicado: (2022)

SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study
por: Dopfer-Jablonka, Alexandra, et al.
Publicado: (2022)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice
por: Do, Kim Thi Hoang, et al.
Publicado: (2023)

Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
por: Arora, Prerna, et al.
Publicado: (2022)

Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1
por: Sidarovich, Anzhalika, et al.
Publicado: (2022)

Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?
por: Gussarow, Daniel, et al.
Publicado: (2021)

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
por: Arora, Prerna, et al.
Publicado: (2021)

SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination
por: Arora, Prerna, et al.
Publicado: (2022)

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
por: Arora, Prerna, et al.
Publicado: (2022)

CRISPR/Cas9 Immunoengineering of Hoxb8-Immortalized Progenitor Cells for Revealing CCR7-Mediated Dendritic Cell Signaling and Migration Mechanisms in vivo
por: Hammerschmidt, Swantje I., et al.
Publicado: (2018)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients
por: Becker, Matthias, et al.
Publicado: (2022)

Health workers’ perception vs medically approved COVID-19 infection risk: the risk communication gap: Ellen Kuhlmann
por: Kuhlmann, E, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
por: Hoffmann, Markus, et al.
Publicado: (2023)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
por: Hoffmann, Markus, et al.
Publicado: (2021)

Healthcare Workers' Perceptions and Medically Approved COVID-19 Infection Risk: Understanding the Mental Health Dimension of the Pandemic. A German Hospital Case Study
por: Kuhlmann, Ellen, et al.
Publicado: (2022)

The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
por: Arora, Prerna, et al.
Publicado: (2022)

Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy
por: Bošnjak, Berislav, et al.
Publicado: (2021)

Efficient IL-2R signaling differentially affects the stability, function, and composition of the regulatory T-cell pool
por: Permanyer, Marc, et al.
Publicado: (2021)

SARS-CoV-2 reinfection()
por: Romera, I., et al.
Publicado: (2021)

Reinfección por SARS-CoV-2
por: Romera, I., et al.
Publicado: (2021)

T cell specific Cxcr5 deficiency prevents rheumatoid arthritis
por: Moschovakis, Georgios L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ul2af45kl3hp6ut0rclcsjbu2l